NAV

Toyocamycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Toyocamycin
DrugBank Accession Number
DB13916
Background

4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 291.2627
Monoisotopic: 291.096753929
Chemical Formula
C12H13N5O4
Synonyms
  • 4-amino-5-cyano-7-(D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidine
  • 7-deaza-7-cyanoadenosine
  • Ahygroscopin-B
  • Cyanotubericidin
  • Siromycin
  • Uramycin B
  • Vengicide
External IDs
  • A-399-Y4
  • Antibiotic 1037
  • Antibiotic A-399-Y4
  • Antibiotic E212
  • E-212
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Toyocamycin is combined with Bupivacaine.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
L7995C4D7F
CAS number
606-58-6
InChI Key
XOKJUSAYZUAMGJ-WOUKDFQISA-N
InChI
InChI=1S/C12H13N5O4/c13-1-5-2-17(11-7(5)10(14)15-4-16-11)12-9(20)8(19)6(3-18)21-12/h2,4,6,8-9,12,18-20H,3H2,(H2,14,15,16)/t6-,8-,9-,12-/m1/s1
IUPAC Name
4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
SMILES
NC1=C2C(=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1)C#N

References

General References
Not Available
ChemSpider
11331
BindingDB
50049823
ChEBI
134606
ChEMBL
CHEMBL99668
ZINC
ZINC000004217594
PDBe Ligand
TO1
PDB Entries
3re4 / 8d1s / 8ov4

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.42 mg/mLALOGPS
logP-0.77ALOGPS
logP-1.4Chemaxon
logS-2.1ALOGPS
pKa (Strongest Acidic)12.46Chemaxon
pKa (Strongest Basic)4.71Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area150.44 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity71.09 m3·mol-1Chemaxon
Polarizability27.45 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0910000000-f59dbb1fa73729a66a20
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0930000000-ac7c11eb9ad62319a73a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0920000000-b895633185ca790b0fef
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a59-0940000000-3577f89d5be7a5c8ffb9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-08fu-1910000000-f9e71c217eef3879baaf
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0900000000-44d76a30ef98da08b06b
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-177.0153993
predicted
DarkChem Lite v0.1.0
[M-H]-164.27298
predicted
DeepCCS 1.0 (2019)
[M+H]+177.2473993
predicted
DarkChem Lite v0.1.0
[M+H]+166.66855
predicted
DeepCCS 1.0 (2019)
[M+Na]+177.1813993
predicted
DarkChem Lite v0.1.0
[M+Na]+173.88655
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2017 20:29 / Updated at June 12, 2020 16:53